New Zealand markets open in 8 hours 23 minutes

Agile Therapeutics, Inc. (AGRX)

OTC Markets OTCQB - OTC Markets OTCQB Delayed price. Currency in USD
Add to watchlist
1.3300+0.9970 (+150.15%)
As of 09:02AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.3330
Open1.2600
Bid1.3000 x 0
Ask1.3500 x 0
Day's range1.2600 - 1.3300
52-week range0.2000 - 3.4000
Volume1,865
Avg. volume67,833
Market cap9.119M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.

    Agile Therapeutics will combine with Insud Pharma’s US Subsidiary, Exeltis, expanding an already significant Women’s Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (

  • GlobeNewswire

    Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

    First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. “We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in th

  • GlobeNewswire

    Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

    Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a wome